Skip to main content
PMC home page
Gut logoLink to Gut
. 1998 Apr;42(4):497–500. doi: 10.1136/gut.42.4.497

Controlled trial of antituberculous chemotherapy in Crohn's disease: a five year follow up study

G Thomas 1, G Swift 1, J Green 1, R Newcombe 1, C Braniff-Mathews 1, J Rhodes 1, S Wilkinson 1, G Strohmeyer 1, G Kreuzpainter 1
PMCID: PMC1727074  PMID: 9616310

Abstract

Background—It has been suggested that Mycobacterium paratuberculosis is the cause of Crohn's disease. In a previous report the immediate effect of two years treatment with antituberculous chemotherapy showed no clinical benefit. 
Aims—To assess both the immediate and longer term effect of treatment on the disease. 
Methods—Patients were followed for five years from their date of entry to the study. One hundred and thirty patients entered the initial study, and of these 111 (81%) were followed regularly. 
Results—Overall, there was no evidence of consistent benefit or disadvantage from antituberculous chemotherapy in any of the assessments made, including the number of acute relapses, surgical episodes, hospital admissions, disease activity, blood tests, or medication required for Crohn's disease during the follow up period. 
Conclusion—The absence of any benefit at the end of the initial two year trial period, and during the three year subsequent follow up, fails to support the hypothesis that mycobacteria play an important part in the pathogenesis of Crohn's disease, or that antituberculous chemotherapy may be of benefit. 



Keywords: Crohn's disease; mycobacteria; antituberculus chemotherapy

Full Text

The Full Text of this article is available as a PDF (97.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Afdhal N. H., Long A., Lennon J., Crowe J., O'Donoghue D. P. Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo. Dig Dis Sci. 1991 Apr;36(4):449–453. doi: 10.1007/BF01298873. [DOI] [PubMed] [Google Scholar]
  2. Best W. R., Becktel J. M., Singleton J. W., Kern F., Jr Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976 Mar;70(3):439–444. [PubMed] [Google Scholar]
  3. Elliott P. R., Burnham W. R., Berghouse L. M., Lennard-Jones J. E., Langman M. J. Sulphadoxine-pyrimethamine therapy in Crohn's disease. Digestion. 1982;23(2):132–134. doi: 10.1159/000198703. [DOI] [PubMed] [Google Scholar]
  4. Graham D. Y., Markesich D. C., Yoshimura H. H. Mycobacteria and inflammatory bowel disease. Results of culture. Gastroenterology. 1987 Feb;92(2):436–442. doi: 10.1016/0016-5085(87)90139-9. [DOI] [PubMed] [Google Scholar]
  5. Hampson S. J., Parker M. C., Saverymuttu S. H., Joseph A. E., McFadden J. J., Hermon-Taylor J. Quadruple antimycobacterial chemotherapy in Crohn's disease: results at 9 months of a pilot study in 20 patients. Aliment Pharmacol Ther. 1989 Aug;3(4):343–352. doi: 10.1111/j.1365-2036.1989.tb00221.x. [DOI] [PubMed] [Google Scholar]
  6. Morgan K. L. Johne's and Crohn's. Chronic inflammatory bowel diseases of infectious aetiology? Lancet. 1987 May 2;1(8540):1017–1019. doi: 10.1016/s0140-6736(87)92280-x. [DOI] [PubMed] [Google Scholar]
  7. Picciotto A., Gesu G. P., Schito G. C., Testa R., Varagona G., Celle G. Antimycobacterial chemotherapy in two cases of inflammatory bowel disease. Lancet. 1988 Mar 5;1(8584):536–537. doi: 10.1016/s0140-6736(88)91334-7. [DOI] [PubMed] [Google Scholar]
  8. Prantera C., Kohn A., Mangiarotti R., Andreoli A., Luzi C. Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol. 1994 Apr;89(4):513–518. [PubMed] [Google Scholar]
  9. Rutgeerts P., Geboes K., Vantrappen G., Van Isveldt J., Peeters M., Penninckx F., Hiele M. Rifabutin and ethambutol do not help recurrent Crohn's disease in the neoterminal ileum. J Clin Gastroenterol. 1992 Jul;15(1):24–28. doi: 10.1097/00004836-199207000-00007. [DOI] [PubMed] [Google Scholar]
  10. Schultz M. G., Rieder H. L., Hersh T., Riepe S. Remission of Crohn's disease with antimycobacterial chemotherapy. Lancet. 1987 Dec 12;2(8572):1391–1392. doi: 10.1016/s0140-6736(87)91276-1. [DOI] [PubMed] [Google Scholar]
  11. Shaffer J. L., Hughes S., Linaker B. D., Baker R. D., Turnberg L. A. Controlled trial of rifampicin and ethambutol in Crohn's disease. Gut. 1984 Feb;25(2):203–205. doi: 10.1136/gut.25.2.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Stanford J. L., White S. A., Burnham W. R., Lennard-Jones J. E., Bird R. G. Mycobacteria and inflammatory bowel disease. Lancet. 1979 Feb 24;1(8113):444–444. doi: 10.1016/s0140-6736(79)90922-x. [DOI] [PubMed] [Google Scholar]
  13. Swift G. L., Srivastava E. D., Stone R., Pullan R. D., Newcombe R. G., Rhodes J., Wilkinson S., Rhodes P., Roberts G., Lawrie B. W. Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease. Gut. 1994 Mar;35(3):363–368. doi: 10.1136/gut.35.3.363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Warren J. B., Rees H. C., Cox T. M. Remission of Crohn's disease with tuberculosis chemotherapy. N Engl J Med. 1986 Jan 16;314(3):182–182. doi: 10.1056/NEJM198601163140314. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES